Xenoscience has been a clinical research site since 2001. Founded by Stephen Flitman, MD as an Alzheimer specialty center, Xenoscience expanded into general neurology and advanced pain management. Joshua Tobin, MD joined in 2006 and added expertise in Migraine and atypical headache, leaving after a distinguished career spanning 15 years. In 2021, Shannon Murphy, PA-C and Kathleen Callahan, PA-C joined the practice and have been invaluable in extending our mission and availability to our patients.

We have been involved in over 200 clinical trials and have contributed to the approvals of many drugs.

These are the treatments which Xenoscience has helped to develop over the years which were eventually approved by the US Food and Drug Administration (FDA). Most have also been approved by the EU equivalent agency, European Medicines Agency.

• Aduhelm
• Aricept
• Axona
• Exelon
• Exelon Patch
• Razadyne
• Razadyne ER

• Aptiom
• Briviact
• Fycompa
• Keppra IV
• Oxtellar XR
• Vimpat
• Xcopri

• Cymbalta
• Savella

• Emgality
• Pediatric Maxalt MLT
• Reyvow
• Ubrelvy

• Aubagio
• Gilenya
• Ocrevus
• Plegridy
• Tecfidera
• Vumerity
• Zeposia

• Lyrica for Diabetic Neuropathy Pain
• Qutenza for HIV Neuropathy Pain

• Nourianz to improve motor function
• Stalevo to improve motor function

A sobering thought: For every drug that is successfully brought to the US market, many more (sometimes as many as hundreds more) have failed in clinical trials.